Xu et al. reported, that 10–20% of patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsed after CD19-specific CAR T cell treatment due to emergence of CD19-negative leukemic cells [4]. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.